Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study
- PMID: 22007042
- PMCID: PMC3209800
- DOI: 10.7326/0003-4819-155-8-201110180-00004
Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study
Erratum in
- Ann Intern Med. 2014 May 6;160(9):658
Abstract
Background: False-positive mammography results are common. Biennial screening may decrease the cumulative probability of false-positive results across many years of repeated screening but could also delay cancer diagnosis.
Objective: To compare the cumulative probability of false-positive results and the stage distribution of incident breast cancer after 10 years of annual or biennial screening mammography.
Design: Prospective cohort study.
Setting: 7 mammography registries in the National Cancer Institute-funded Breast Cancer Surveillance Consortium.
Participants: 169,456 women who underwent first screening mammography at age 40 to 59 years between 1994 and 2006 and 4492 women with incident invasive breast cancer diagnosed between 1996 and 2006.
Measurements: False-positive recalls and biopsy recommendations stage distribution of incident breast cancer.
Results: False-positive recall probability was 16.3% at first and 9.6% at subsequent mammography. Probability of false-positive biopsy recommendation was 2.5% at first and 1.0% at subsequent examinations. Availability of comparison mammograms halved the odds of a false-positive recall (adjusted odds ratio, 0.50 [95% CI, 0.45 to 0.56]). When screening began at age 40 years, the cumulative probability of a woman receiving at least 1 false-positive recall after 10 years was 61.3% (CI, 59.4% to 63.1%) with annual and 41.6% (CI, 40.6% to 42.5%) with biennial screening. Cumulative probability of false-positive biopsy recommendation was 7.0% (CI, 6.1% to 7.8%) with annual and 4.8% (CI, 4.4% to 5.2%) with biennial screening. Estimates were similar when screening began at age 50 years. A non-statistically significant increase in the proportion of late-stage cancers was observed with biennial compared with annual screening (absolute increases, 3.3 percentage points [CI, -1.1 to 7.8 percentage points] for women age 40 to 49 years and 2.3 percentage points [CI, -1.0 to 5.7 percentage points] for women age 50 to 59 years) among women with incident breast cancer.
Limitations: Few women underwent screening over the entire 10-year period. Radiologist characteristics influence recall rates and were unavailable. Most mammograms were film rather than digital. Incident cancer was analyzed in a small sample of women who developed cancer.
Conclusion: After 10 years of annual screening, more than half of women will receive at least 1 false-positive recall, and 7% to 9% will receive a false-positive biopsy recommendation. Biennial screening appears to reduce the cumulative probability of false-positive results after 10 years but may be associated with a small absolute increase in the probability of late-stage cancer diagnosis.
Primary funding source: National Cancer Institute.
Comment in
-
Frequency, digital technology, and the efficiency of screening mammography.Ann Intern Med. 2011 Oct 18;155(8):554-5. doi: 10.7326/0003-4819-155-8-201110180-00014. Ann Intern Med. 2011. PMID: 22007048 No abstract available.
Summary for patients in
-
Summaries for patients: the benefits and harms of more and less frequent screening mammography.Ann Intern Med. 2011 Oct 18;155(8):I14. doi: 10.7326/0003-4819-155-8-201110180-00001. Ann Intern Med. 2011. PMID: 22007059 No abstract available.
Similar articles
-
Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography.JAMA Netw Open. 2022 Mar 1;5(3):e222440. doi: 10.1001/jamanetworkopen.2022.2440. JAMA Netw Open. 2022. PMID: 35333365 Free PMC article.
-
Association Between False-Positive Results and Return to Screening Mammography in the Breast Cancer Surveillance Consortium Cohort.Ann Intern Med. 2024 Oct;177(10):1297-1307. doi: 10.7326/M24-0123. Epub 2024 Sep 3. Ann Intern Med. 2024. PMID: 39222505
-
Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age.Cancer. 2013 Nov 15;119(22):3959-67. doi: 10.1002/cncr.28310. Epub 2013 Aug 26. Cancer. 2013. PMID: 24037812 Free PMC article.
-
Benefits and Harms of Breast Cancer Screening: A Systematic Review.JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183. JAMA. 2015. PMID: 26501537 Review.
-
Digital Breast Tomosynthesis with Hologic 3D Mammography Selenia Dimensions System for Use in Breast Cancer Screening: A Single Technology Assessment [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4. Report from the Norwegian Institute of Public Health No. 2017-08. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4. Report from the Norwegian Institute of Public Health No. 2017-08. PMID: 29553669 Free Books & Documents. Review.
Cited by
-
Machine learning can reliably predict malignancy of breast lesions based on clinical and ultrasonographic features.Breast Cancer Res Treat. 2024 Jul 13. doi: 10.1007/s10549-024-07429-0. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39002069
-
Patient counseling for breast cancer screening: Taking changes to USPSTF recommendations into account.OBG Manag. 2023 Dec;35(12):43-49. doi: 10.12788/obgm.0334. OBG Manag. 2023. PMID: 38835939 Free PMC article.
-
Using Discrete Event Simulation to Design and Assess an AI-aided Workflow for Same-day Diagnostic Testing of Women Undergoing Breast Screening.AMIA Jt Summits Transl Sci Proc. 2024 May 31;2024:314-323. eCollection 2024. AMIA Jt Summits Transl Sci Proc. 2024. PMID: 38827101 Free PMC article.
-
ESR Essentials: screening for breast cancer - general recommendations by EUSOBI.Eur Radiol. 2024 Oct;34(10):6348-6357. doi: 10.1007/s00330-024-10740-5. Epub 2024 Apr 24. Eur Radiol. 2024. PMID: 38656711 Free PMC article.
-
Screening mammography frequency following dense breast notification among a predominantly Hispanic/Latina screening cohort.Cancer Causes Control. 2024 Aug;35(8):1133-1142. doi: 10.1007/s10552-024-01871-7. Epub 2024 Apr 12. Cancer Causes Control. 2024. PMID: 38607569
References
-
- Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2002;137:347–360. - PubMed
-
- Smith RA, Duffy SW, Gabe R, Tabar L, Yen AM, Chen TH. The randomized trials of breast cancer screening: what have we learned? Radiologic Clinics of North America. 2004;42:793–806. - PubMed
-
- Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909–919. - PubMed
-
- Tabar L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000;38(4):625–651. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 CA063740/CA/NCI NIH HHS/United States
- U01 CA070040/CA/NCI NIH HHS/United States
- RC2CA148577/CA/NCI NIH HHS/United States
- U01CA70013/CA/NCI NIH HHS/United States
- U01 CA086082/CA/NCI NIH HHS/United States
- U01CA63736/CA/NCI NIH HHS/United States
- U01CA86082/CA/NCI NIH HHS/United States
- R03 CA150007-01/CA/NCI NIH HHS/United States
- R03CA150007/CA/NCI NIH HHS/United States
- U01CA70040/CA/NCI NIH HHS/United States
- U01CA63740/CA/NCI NIH HHS/United States
- U01 CA063736-10/CA/NCI NIH HHS/United States
- U01 CA070040-10/CA/NCI NIH HHS/United States
- U01CA69976/CA/NCI NIH HHS/United States
- U01 CA063731/CA/NCI NIH HHS/United States
- U01 CA086076/CA/NCI NIH HHS/United States
- R03 CA150007/CA/NCI NIH HHS/United States
- RC2 CA148577/CA/NCI NIH HHS/United States
- U01 CA069976/CA/NCI NIH HHS/United States
- U01CA86076/CA/NCI NIH HHS/United States
- U01 CA063736/CA/NCI NIH HHS/United States
- U01 CA086082-10/CA/NCI NIH HHS/United States
- U01 CA063731-10/CA/NCI NIH HHS/United States
- U01 CA069976-10/CA/NCI NIH HHS/United States
- RC2 CA148577-01/CA/NCI NIH HHS/United States
- U01 CA086076-10/CA/NCI NIH HHS/United States
- U01 CA063740-11/CA/NCI NIH HHS/United States
- U01 CA070013-10/CA/NCI NIH HHS/United States
- U01 CA070013/CA/NCI NIH HHS/United States
- U01CA63731/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical